Synapse - Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: Efficacy and analysis of risk factors associated with poor stem cell collection efficiency*

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: Efficacy and analysis of risk factors associated with poor stem cell collection efficiency* Journal Article

Authors:	Ogunniyi, A.; Rodriguez, M.; Devlin, S.; Adel, N.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A.; Koehne, G.; Mailankody, S.; Korde, N.; Reich, L.; Landgren, O.; Giralt, S.; Hassoun, H.
Article Title:	Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: Efficacy and analysis of risk factors associated with poor stem cell collection efficiency*
Abstract:	Plerixafor (P), an agent that selectively and reversibly binds to the chemokine receptor CXCR4, has been approved in combination with G-CSF (P + G-CSF) for stem cell (SC) mobilization in patients with multiple myeloma (MM). The goal of this study was to determine the SC collection success rate of P + G-CSF using a clinically relevant outcome defined as the ability to collect at least 5 × 106 CD34+ cells/kg to allow safely two transplants, and identify risk factors impacting SC mobilization. One hundred and thirty-eight patients were mobilized with P + G-CSF upfront following induction. The SC collection success rate was 92.8%. We identified exposure to lenalidomide alone (p =.038), WBC count <4 × 103/mcL prior to mobilization (p =.01) and non-African American race (p =.019), as risk factors for low efficiency by multivariate analysis. This study demonstrates that P + G-CSF is highly efficient in MM patients and provides strong support for its upfront use in SC collection for MM patients. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Keywords:	multiple myeloma; risk factors; stem cell; plerixafor; efficiency; mobilization
Journal Title:	Leukemia and Lymphoma
Volume:	58
Issue:	5
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2017-01-01
Start Page:	1123
End Page:	1129
Language:	English
DOI:	10.1080/10428194.2016.1239261
PROVIDER:	scopus
PUBMED:	27735212
PMCID:	PMC5640442
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991035975&doi=10.1080%2f10428194.2016.1239261&partnerID=40&md5=ea523fd28907bf506eb63dab796dbe68
Notes:	Article -- Export Date: 2 March 2017 -- Source: Scopus